Number of participants experiencing any serious adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Tinnitus symptom severity · adults with subjective idiopathic tinnitus
1 finding from 1 review
Significant adverse effect: increase in self‐reported tinnitus loudness · adults with subjective idiopathic tinnitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · adults with subjective idiopathic tinnitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anxiety · adults with subjective idiopathic tinnitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · adults with subjective idiopathic tinnitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects associated with wearing the device (such as pain, discomfort, tenderness or skin irritation, or ear infections) · adults with subjective idiopathic tinnitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ‐ Gemcitabine plus topoisomerase inhibitor · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus topoisomerase inhibitor compared with gemcitabine alone (high certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus taxane · advanced pancreatic cancer
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus taxane compared with gemcitabine alone (high certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus other agent(s) · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus other agent(s) compared with gemcitabine alone (low certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus platinum agent · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus fluoropyrimidine · advanced pancreatic cancer
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus fluoropyrimidine compared with gemcitabine alone (high certainty).
1 finding from 1 review
Clinical cure · participants with confirmed toenail onychomycosis
It is very uncertain whether combination terbinafine plus azole changes clinical cure compared with terbinafine monotherapy (very low certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
It is very uncertain whether combination terbinafine plus azole changes mycological cure compared with terbinafine monotherapy (very low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Combination terbinafine plus azole showed no clear difference in adverse events compared with terbinafine monotherapy (low certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions due to exacerbations: number of participants · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with current best practice (low certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to lower patients with exacerbations treated with oral steroids compared with current best practice (moderate certainty).
1 finding from 1 review